UNSPSC 51183000: Combination anterior pituitary

This classification denotes combination drugs that consist of various combined compounds that deal with the adenohypophysis, or the anterior glandular lobe of the pituitary gland, hence the term ANTERIOR PITUITARY. Typical combination anterior pituitary constituients are corticotropin and zinc hydroxide.

UNSPSC 51183000 Combination anterior pituitary is a Class code covering pharmaceutical manufacturing and supply, where state and local governments purchase generic multi-source drugs and over-the-counter products through cooperative purchasing agreements and direct manufacturer contracts. The scope of work encompasses product sourcing, regulatory compliance documentation, pricing administration, and supply-chain coordination with authorized pharmaceutical wholesalers. State and local procurement under this code centers on cooperative purchasing vehicles rather than individual agency RFPs — the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers the primary recent opportunity, which draws participation from multiple states including Oregon and Minnesota. Vendors must meet FDA requirements, maintain cGMP and Drug Supply Chain Security Act (DSCSA) certifications, carry comprehensive insurance ($5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability), and establish relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC.

The MMCAP generic multi-source pharmaceuticals and OTC products RFP, posted January 20, 2026 with a March 26, 2026 response deadline, represents the primary recent activity under this code. The procurement establishes multiple contracts effective July 1, 2026, for a two-year term with optional extensions, and awards will be weighted on price competitiveness (75 percent), fixed pricing compliance (10 percent), EDI capability and administrative fee compliance (5 percent each), and pricing format submission standards (5 percent). Vendors must submit National Drug Code (NDC) information, SKUs, UPCs, generic descriptions, strength, dosage forms, and manufacturing locations through the ePro procurement system, with pricing options including flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures. All products must be available by May 15, 2026, possess FDA approval with expiration dates at least one year from manufacture and a minimum six-month shelf life, and comply with chargeback systems and class-of-trade requirements across at least two authorized wholesalers. The RFP does not disclose specific award values but applies a 3 percent administrative fee on contract purchases with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper denials.